Effects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male Monkeys
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists, used for the treatment of type 2 diabetes, have caused hyperplasia/neoplasia of thyroid C cells in rodent carcinogenicity studies. Studies in monkeys have not identified an effect of GLP-1 receptor agonists on thyroid C cells; however, group sizes were small. Dulaglutide is a once-weekly, long-acting human GLP-1 receptor agonist recently approved in the United States and the European Union. The objective of this study was to determine whether dulaglutide altered C-cell mass in monkeys. Male cynomolgus monkeys (20 per group) were sc injected with dulaglutide 8.15 mg/kg (∼500-fold maximum human plasma exposure) or a vehicle control twice weekly for 52 weeks. Basal and calcium gluconate-stimulated serum calcitonin concentrations were obtained at 3, 6, 9, and 12 months. Thyroid glands were weighed, fixed, and sectioned at 500-μm intervals. C-cell volumes were measured using an automated image analysis. C-cell proliferation was estimated using Ki67/calcitonin colabeling and cell counting. Administration of dulaglutide 8.15 mg/kg twice weekly for 52 weeks did not increase serum calcitonin in monkeys or affect thyroid weight, histology, C-cell proliferation, or absolute/relative C-cell volume. This study represents a comprehensive evaluation of the monkey thyroid C cells after dosing with a GLP-1 receptor agonist, with a large group size, and measurement of multiple relevant parameters. The lack of effect of dulaglutide on C cells is consistent with other studies in monkeys using GLP-1 receptor agonists and suggests that nonhuman primates are less sensitive than rodents to the induction of proliferative changes in thyroid C cells by GLP-1 receptor agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 4×
“The increased incidence of thyroid C-cell hyperplasia and neoplasia in rodents caused by long-acting GLP-1 receptor agonists such as liraglutide (13), exenatide extended-release (14), and lixisenatide (15, 16) were carefully considered during the regulatory approval process for these agents (17) and are prominently id…”
BackgroundResultInfluentialNauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
Hegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194 · cited 1×
“In two separate human clinical trials of different GLP-1 receptor agonists, 2 years of liraglutide treatment and 2 years of dulaglutide treatment did not significantly increase calcitonin secretion, and overall mean serum calcitonin concentrations remained at the lower end of the normal range (30, 31).”
BackgroundByrd, R. A., Sorden, S. D., Ryan, T., Pienkowski, T., LaRock, R., Quander, R., Wijsman, J. A., Smith, H. W., Blackbourne, J. L., Rosol, T. J., et al. (2015) · Endocrinology · doi:10.1210/en.2014-1722 · Cited by 36
Self-citation
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“In contrast, the density of GLP-1Rs on monkey and human thyroid cells is extremely low, and sustained GLP-1R agonism does not cause calcitonin secretion, C cell hyperplasia, or MTC in non-human primates (Bjerre Knudsen et al., 2010; Vahle et al., 2015).”
BackgroundFilippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Baxter, S. M., Lund, L. C., Andersen, J. H., Brix, T. H., Hegedüs, L., Hsieh, M. H.-C., Su, C. T.-T., Cheng, M. C.-Y., Chang, Z. C.-J., Lai, E. C.-C., et al. (2025) · Thyroid® · doi:10.1089/thy.2024.0387 · Cited by 81
“9,11 Several observational studies have evaluated this association, reporting con-fl icting fi ndings.”
Use and importance of nonhuman Primates in metabolic disease research: current state of the field
Havel, P. J., Kievit, P., Comuzzie, A. G., & Bremer, A. A. (2017) · ILAR Journal · doi:10.1093/ilar/ilx031 · Cited by 75
Byrd, R. A., Sorden, S. D., Ryan, T., Pienkowski, T., LaRock, R., Quander, R., Wijsman, J. A., Smith, H. W., Blackbourne, J. L., Rosol, T. J., et al. (2015) · Endocrinology · doi:10.1210/en.2014-1722 · Cited by 36
Self-citation
Metadata
- Authors
- Vahle, J. L., Byrd, R. A., Blackbourne, J. L., Martin, J. A., Sorden, S. D., Ryan, T., Pienkowski, T., Wijsman, J. A., Smith, H. W., & Rosol, T. J.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2015-04-10
- Volume
- 156
- Issue
- 7
- Pages
- 2409-2416
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2124733490
- Cited by
- 16
- References
- 4
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.